<DOC>
	<DOCNO>NCT00495222</DOCNO>
	<brief_summary>The objective feasibility trial evaluate Ethicon Endo-Surgery Endoscopic Suturing System ( ESS ) tissue apposition reduction size dilate GJ anastomosis subject regain weight successful weight loss follow gastric bypass . Post-procedure weight follow ass whether weight loss resume . The ESS FDA-cleared ( 510 ( k ) ) sterile , single-use , disposable suture system indicate endoscopic placement suture ( ) approximation soft tissue . It design facilitate endoscopic gastrointestinal procedure .</brief_summary>
	<brief_title>Endoscopic Suturing System Tissue Apposition</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Subjects must fulfill follow criterion enter study : Review sign informed consent ; Between 21 65 year age ( inclusive ) time trial enrollment ; Documented RouxenY Gastric Bypass ( RYGB ) surgery date Documented baseline weight time RYGB procedure ; &gt; 12 month post RYGB ) ; Body mass Index ( BMI ) &gt; 30 least 20 pound excess postRYGB weight nadir ; Patients initially achieve least 50 % excess weight loss ( EWL ) post RYGB ; Visible anastomotic junction ( gastric pouch Rouxlimb ) ; Stoma size screen &gt; 15mm ; Negative serum pregnancy test woman childbearing potential . Exclusion Criteria Subjects exclude trial following : Documented history esophageal pathology ( e.g. , esophageal varix , Barrett 's Esophagus ) ; American Anesthesia Association ( ASA ) Class IV V and/or contraindication monitor anesthesia ; Documented history GJ anastomosis stricture ( within 6 month ) ; Documented history previous RYGB revision ; Presence document presence gastric/duodenal ulcer ; Presence sepsis ; Medical physical endoscopic contraindication , include esophageal varix bleeding , laryngeal perforation , trauma pharynx , aspiration pneumonia , acute peritonitis , condition general endoscopic technique and/or placement overtube contraindicate ; Chronic NonSteroidal AntiInflammatory Drug ( NSAID ) use ( subject take single aspirin tablet per day cardioprotection consider acceptable ) ; Uncontrolled diabetes ; Physical psychological condition would impair trial participation per investigator discretion ; Bingeeating similar eating disorder ; Unable unwilling attend followup visit examination ; Concurrent surgical procedure ( intraoperative exclusion ESS procedure ) ; Participation investigational device drug trial within 30 day prior enrollment ; Any condition , preclude compliance trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>gastrojejunostomy</keyword>
	<keyword>stoma</keyword>
</DOC>